This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Hefame group probed in Spain over possible breach of merger conditions

( February 12, 2025, 14:14 GMT | Official Statement) -- MLex Summary: Hermandad Farmacéutica del Mediterráneo, or Hefame, a Spanish cooperative which distributes pharmaceutical products, is under investigation by the Spanish competition authority to shed light into whether it failed to implement the conditions it agreed to in a move to win approval for its takeover of Farmacéutica Conquense, or Cofarcu. In 2022, the watchdog cleared the merger in its initial review phase, but tied the approval to a set of commitments. The office has now three months for the probe and resolution of the case.  Statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login